1 – 10 of 2796
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Time to diagnose and improve outcomes in people with breathlessness: a call for action
- Contribution to journal › Letter
-
Mark
The rise and fall of a paradigm and conceiving a new hypothesis for type 1 diabetes
- Contribution to journal › Letter
- 2025
-
Mark
Reply to Zhang et al. : Parallel vector memories are required to explain all behavioral data in navigating bumblebees
- Contribution to journal › Letter
-
Mark
Challenging the green machine : Rejoinder to Schwartzman
- Contribution to journal › Letter
-
Mark
Eosinophil-Derived Neurotoxin Determinants and Reference Values in a Swedish Middle-Aged General Population
- Contribution to journal › Letter
-
Mark
PERCC1-Related Congenital Enteropathy
- Contribution to journal › Letter
-
Mark
Response to the comment on 'The coexistence of diabetes, hypertension and obesity is associated with worse pain outcomes following exercise for osteoarthritis: A cohort study on 80 893 patients'
- Contribution to journal › Letter
-
Mark
Para-Phenylenediamine in Commercial Henna Products
- Contribution to journal › Letter
-
Mark
Spread of the FAR-MRSA clone, a fusidic acid- and meticillin-resistant Staphylococcus aureus ST121, Europe, 2014 to 2024.
(2025) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 30(28).
- Contribution to journal › Letter
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
- Contribution to journal › Letter
